Search

Your search keyword '"Gibbons, Don L."' showing total 1,057 results

Search Constraints

Start Over You searched for: Author "Gibbons, Don L." Remove constraint Author: "Gibbons, Don L."
1,057 results on '"Gibbons, Don L."'

Search Results

1. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

2. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

4. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

5. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

6. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer

7. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

8. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing

9. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

10. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma

11. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages

12. Archival single-cell genomics reveals persistent subclones during DCIS progression

13. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

14. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.

15. PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

16. Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma

17. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer

19. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer

20. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment

21. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

23. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

24. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

25. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection

26. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes

27. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

28. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

29. Abstract A022: Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA

30. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

32. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival

34. Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma

36. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

37. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

38. CD8+ T cells inhibit metastasis and CXCL4 regulates its function

39. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

40. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC

41. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

42. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.

43. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

44. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

45. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

47. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

48. Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

49. Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

50. Data from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources